JAK2 and hepatocellular carcinoma: The JAK2/STAT3 pathway is activated downstream B7-H3-induced signaling which is in agreement with reports of the B7-H3 role in multiple myeloma, hepatocellular carcinoma, and glioma cell lines [20–22].